bentov
Fentanyl-laced urine.
- Joined
- Aug 10, 2026
- Posts
- 722
- Reputation
- 1,994
Memantine and Cerebrolysin for Neuroprotection
Greetings and Salutations my name is Bentov. This guide is about the neuroprotective properties of Memantine and Cerebrolysin. Some people found this very interesting and so did I, so I made a thread about it. Oh yeah, I always Implemented a part about clinical research that has been done on the two compounds, you can dnr that if you want.
Hope you enjoy the read.
Table of Contents
Glossary
Introduction
Glutamate and Excitotoxicity
Memantine
Cerebrolysin
Comparison of Memantine and Cerebrolysin + Complementarity
Conclusion
Sources
Glossary
Introduction
Neuronal health depends on a complex balance between excitatory and inhibitory neurotransmission, appropriate calcium regulation, mitochondrial function, and the activity of cellular survival pathways. Disruptions to these processes can contribute to neuronal dysfunction and, under certain conditions, neuronal injury.
AAS exposure has been investigated in relation to several of these neurological processes, including glutamate and GABA signalling, dopaminergic activity, oxidative stress, neuroinflammation, and neuroplasticity.
Two substances that have attracted interest for their potential effects on neuronal health are memantine and Cerebrolysin. Memantine is a non-competitive NMDA receptor antagonist primarily used in the treatment of Alzheimer's disease. Cerebrolysin is a peptide-containing preparation investigated for potential neurotrophic, neuroprotective, and neurorestorative effects.
Glutamate and Excitotoxicity
Glutamate is the primary excitatory neurotransmitter in the central nervous system. It plays an essential role in neuronal communication, learning, memory, and synaptic plasticity. Its activity is regulated through several receptor types, particularly NMDA, AMPA, and kainate receptors.
NMDA Receptors
NMDA receptors are ionotropic glutamate receptors that allow calcium and other ions to pass through neuronal membranes when activated under appropriate conditions. They are particularly important for synaptic plasticity and long-term potentiation, a process associated with learning and memory. However, excessive NMDA receptor activation can produce an abnormal increase in intracellular calcium. This can activate damaging intracellular pathways, contribute to mitochondrial dysfunction, increase oxidative stress, and ultimately result in neuronal injury.
Excitotoxicity
Excitotoxicity refers to neuronal injury associated with excessive excitatory neurotransmission, particularly excessive glutamate receptor activation. It has been investigated in several neurological conditions, including:
Greetings and Salutations my name is Bentov. This guide is about the neuroprotective properties of Memantine and Cerebrolysin. Some people found this very interesting and so did I, so I made a thread about it. Oh yeah, I always Implemented a part about clinical research that has been done on the two compounds, you can dnr that if you want.
Hope you enjoy the read.
This is not medical advice.
Table of Contents
Glossary
Introduction
Glutamate and Excitotoxicity
Memantine
Cerebrolysin
Comparison of Memantine and Cerebrolysin + Complementarity
Conclusion
Sources
Glossary
AAS: Anabolic-androgenic steroids.
NMDAR: N-methyl-D-aspartate receptor, a subtype of glutamate receptor.
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor.
Excitotoxicity: Neuronal damage associated with excessive activation of excitatory receptors.
Neuroinflammation: Inflammatory activity within the nervous system.
Oxidative stress: An imbalance between reactive oxygen species and the body's antioxidant defences.
ROS: Reactive oxygen species.
Neurosteroids: Steroids produced in or acting on the nervous system.
GABA: Gamma-aminobutyric acid, the main inhibitory neurotransmitter in the brain.
BDNF: Brain-derived neurotrophic factor.
CREB: cAMP response element-binding protein.
PI3K/Akt: An intracellular signalling pathway involved in cell survival, growth, and resistance to certain forms of cellular stress.
Apoptosis: Programmed cell death.
Neuroplasticity: The nervous system's ability to adapt and reorganise.
Neurorestoration: Processes associated with recovery or repair of nervous-system function.
HPG axis: Hypothalamic-pituitary-gonadal axis.
Preclinical evidence: Research conducted in laboratory or animal models before clinical testing in humans.
RCT: Randomised controlled trial.
NMDAR: N-methyl-D-aspartate receptor, a subtype of glutamate receptor.
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor.
Excitotoxicity: Neuronal damage associated with excessive activation of excitatory receptors.
Neuroinflammation: Inflammatory activity within the nervous system.
Oxidative stress: An imbalance between reactive oxygen species and the body's antioxidant defences.
ROS: Reactive oxygen species.
Neurosteroids: Steroids produced in or acting on the nervous system.
GABA: Gamma-aminobutyric acid, the main inhibitory neurotransmitter in the brain.
BDNF: Brain-derived neurotrophic factor.
CREB: cAMP response element-binding protein.
PI3K/Akt: An intracellular signalling pathway involved in cell survival, growth, and resistance to certain forms of cellular stress.
Apoptosis: Programmed cell death.
Neuroplasticity: The nervous system's ability to adapt and reorganise.
Neurorestoration: Processes associated with recovery or repair of nervous-system function.
HPG axis: Hypothalamic-pituitary-gonadal axis.
Preclinical evidence: Research conducted in laboratory or animal models before clinical testing in humans.
RCT: Randomised controlled trial.
Introduction
Neuronal health depends on a complex balance between excitatory and inhibitory neurotransmission, appropriate calcium regulation, mitochondrial function, and the activity of cellular survival pathways. Disruptions to these processes can contribute to neuronal dysfunction and, under certain conditions, neuronal injury.
AAS exposure has been investigated in relation to several of these neurological processes, including glutamate and GABA signalling, dopaminergic activity, oxidative stress, neuroinflammation, and neuroplasticity.
Two substances that have attracted interest for their potential effects on neuronal health are memantine and Cerebrolysin. Memantine is a non-competitive NMDA receptor antagonist primarily used in the treatment of Alzheimer's disease. Cerebrolysin is a peptide-containing preparation investigated for potential neurotrophic, neuroprotective, and neurorestorative effects.
Glutamate and Excitotoxicity
Glutamate is the primary excitatory neurotransmitter in the central nervous system. It plays an essential role in neuronal communication, learning, memory, and synaptic plasticity. Its activity is regulated through several receptor types, particularly NMDA, AMPA, and kainate receptors.
NMDA Receptors
NMDA receptors are ionotropic glutamate receptors that allow calcium and other ions to pass through neuronal membranes when activated under appropriate conditions. They are particularly important for synaptic plasticity and long-term potentiation, a process associated with learning and memory. However, excessive NMDA receptor activation can produce an abnormal increase in intracellular calcium. This can activate damaging intracellular pathways, contribute to mitochondrial dysfunction, increase oxidative stress, and ultimately result in neuronal injury.
Excitotoxicity
Excitotoxicity refers to neuronal injury associated with excessive excitatory neurotransmission, particularly excessive glutamate receptor activation. It has been investigated in several neurological conditions, including:
- Ischaemic stroke
- Traumatic brain injury
- Neurodegenerative diseases
- Certain forms of neuronal injury
The process involves several interacting mechanisms:
- Excessive glutamate receptor activation.
- Increased intracellular calcium.
- Activation of calcium-dependent enzymes.
- Mitochondrial dysfunction and increased oxidative stress.
- Activation of pathways associated with neuronal injury and cell death.
Relevance to AAS
Glutamatergic signalling is one of several neurological systems investigated in relation to AAS exposure. In preclinical cell culture studies, supraphysiological doses of nandrolone and testosterone were shown to amplify NMDA-mediated excitotoxic neuronal death in vitro. Structural MRI studies comparing long-term, high-dose AAS gymcels to non-using gymcels found thinner cerebral cortex regions (especially in areas governing executive function and impulse control) and accelerated brain-age estimates.
Memantine
Overview
Memantine is a non-competitive NMDA receptor antagonist used clinically for moderate-to-severe Alzheimer's disease. Unlike competitive antagonists, which compete with glutamate for receptor binding, memantine acts within the NMDA receptor-associated ion channel. It has voltage-dependent and relatively low-to-moderate affinity channel-blocking properties. This allows it to reduce certain forms of excessive receptor activity while preserving some physiological NMDA receptor signalling.
The Mechanism
Under normal physiological conditions, NMDA receptors contribute to neuronal communication, synaptic plasticity, and memory formation. Excessive activation can lead to increased calcium influx and activation of intracellular pathways associated with neuronal injury.
Memantine reduces excessive NMDA receptor activity by blocking the associated ion channel.
As demonstrated in foundational preclinical reviews, unlike high-affinity blockers (such as MK-801) that disrupt normal cognition, memantine blocks prolonged, tonic calcium influx during excitotoxic stress while rapidly unbinding during brief, physiological glutamate bursts thereby preserving normal learning and memory signaling.
Kinetics:
Neuroprotective Properties
Research has examined whether memantine can limit excitotoxic damage and protect neurons from excessive NMDA receptor activation. Its potential neuroprotective effects are generally associated with:
- Regulation of excessive NMDA receptor activity.
- Reduction of pathological calcium influx.
- Limitation of downstream excitotoxic signalling.
- Preservation of neuronal function under certain pathological conditions.
Clinical Research
Memantine has been evaluated in clinical trials involving Alzheimer's disease and other neurological conditions, here are some studies that I found:
Moderate-to-Severe Alzheimer's Monotherapy: A 28-week Phase III RCT of 252 patients showed that memantine (20 mg/day) significantly slowed clinical deterioration in cognition, daily functioning, and global clinical impression compared to placebo.
Combination Therapy: A 24-week RCT of 404 moderate-to-severe Alzheimer's patients already taking donepezil demonstrated that adding memantine produced significantly better cognitive, functional, and behavioral outcomes than donepezil plus placebo.
Mild-to-Moderate Alzheimer's: A 24-week RCT testing memantine in earlier-stage patients found no statistically significant difference between memantine and placebo at the 24-week endpoint, suggesting clinical efficacy is concentrated in conditions with more advanced, sustained excitotoxic stress rather than mild impairment.
Overall, these trials show that memantine can provide measurable clinical benefits in certain neurological conditions.
Moderate-to-Severe Alzheimer's Monotherapy: A 28-week Phase III RCT of 252 patients showed that memantine (20 mg/day) significantly slowed clinical deterioration in cognition, daily functioning, and global clinical impression compared to placebo.
Combination Therapy: A 24-week RCT of 404 moderate-to-severe Alzheimer's patients already taking donepezil demonstrated that adding memantine produced significantly better cognitive, functional, and behavioral outcomes than donepezil plus placebo.
Mild-to-Moderate Alzheimer's: A 24-week RCT testing memantine in earlier-stage patients found no statistically significant difference between memantine and placebo at the 24-week endpoint, suggesting clinical efficacy is concentrated in conditions with more advanced, sustained excitotoxic stress rather than mild impairment.
Overall, these trials show that memantine can provide measurable clinical benefits in certain neurological conditions.
Relevance to AAS
The relevance of memantine to AAS-associated neurological effects is based primarily on its influence on NMDA receptor activity. In vitro research suggests high-dose androgens can heighten neuronal sensitivity to NMDA-driven excitotoxicity. Memantine could protect neurons from AAS neurotoxicity by blocking pathological calcium influx without disrupting normal brain signaling.
Cerebrolysin
Overview
Cerebrolysin is a pharmaceutical preparation containing peptides and amino acids derived from purified porcine brain proteins. Research has focused on its possible ability to support neuronal survival and recovery, particularly in conditions involving neurological injury. Unlike memantine, which primarily acts through a defined receptor mechanism, Cerebrolysin has been proposed to influence several biological pathways involved in neuronal survival and plasticity.
The Mechanisms
Neurotrophic activity: Preclinical in vitro and transgenic animal studies indicate that Cerebrolysin mimics the activity of endogenous neurotrophic factors (such as BDNF and NGF), supporting neuronal development, survival, differentiation, and maintenance.
Neuroplasticity: Cerebrolysin has been investigated for potential effects on processes associated with synaptic function, reduced amyloid-related synaptic toxicity, and neuronal adaptation.
Oxidative stress: Some experimental studies suggest that Cerebrolysin may influence oxidative stress-related pathways that otherwise damage membranes, proteins, and mitochondrial structures.
Intracellular survival pathways: A study shows that Cerebrolysin activates intracellular signalling pathways associated with PI3K/Akt and CREB, reducing markers of apoptosis (programmed cell death) and supporting cellular survival.
These are the general neurotrophin-signalling pathways (PI3K/Akt, CREB). Cerebrolysin is proposed to act on these pathways.
Clinical Research
Cerebrolysin has been studied in stroke, traumatic brain injury, and dementia, here are some studies that I found:
Acute Ischemic Stroke – CASTA Trial: A large double-blind RCT of 1,070 stroke patients receiving IV Cerebrolysin for 10 days found no statistically significant difference in the primary 90-day global recovery endpoint compared to placebo, though a post-hoc subgroup analysis suggested a favorable trend in patients with more severe initial strokes.
Stroke Motor Recovery – CARS Trial: An RCT of 208 stroke patients pairing early rehabilitation with 21 days of Cerebrolysin reported significantly greater upper-limb motor recovery and lower disability scores at 90 days versus placebo plus rehabilitation.
Traumatic Brain Injury – CAPTAIN I & II Trials: Double-blind RCTs in moderate-to-severe TBI patients reported improvements on multidimensional neurorecovery scales (combining cognitive, motor, and behavioral metrics) at 30 and 90 days compared to standard care.
Evidence Quality Assessment – Cochrane Systematic Reviews: Independent meta-analyses of all randomized trials for acute ischemic stroke concluded that high-quality evidence does not show a clear benefit in preventing death or dependency, noting methodological limitations and a slight increase in non-fatal serious adverse events in some trials.
Acute Ischemic Stroke – CASTA Trial: A large double-blind RCT of 1,070 stroke patients receiving IV Cerebrolysin for 10 days found no statistically significant difference in the primary 90-day global recovery endpoint compared to placebo, though a post-hoc subgroup analysis suggested a favorable trend in patients with more severe initial strokes.
Stroke Motor Recovery – CARS Trial: An RCT of 208 stroke patients pairing early rehabilitation with 21 days of Cerebrolysin reported significantly greater upper-limb motor recovery and lower disability scores at 90 days versus placebo plus rehabilitation.
Traumatic Brain Injury – CAPTAIN I & II Trials: Double-blind RCTs in moderate-to-severe TBI patients reported improvements on multidimensional neurorecovery scales (combining cognitive, motor, and behavioral metrics) at 30 and 90 days compared to standard care.
Evidence Quality Assessment – Cochrane Systematic Reviews: Independent meta-analyses of all randomized trials for acute ischemic stroke concluded that high-quality evidence does not show a clear benefit in preventing death or dependency, noting methodological limitations and a slight increase in non-fatal serious adverse events in some trials.
Relevance to AAS
Given its potential effects on neurotrophic signalling, neuronal survival, and plasticity, Cerebrolysin is worth discussing in the context of AAS-related neurological research, I found an interesting MRI study that was related to this: Kanayama et al., 2015; Bjørnebekk et al., 2017. This study compared experienced male AAS gymcels against non-using gymcels to isolate the neurological effects of prolonged hormone exposure from resistance training alone. The initial 2015 Harvard/McLean study (comparing 10 long-term users to 10 controls) identified right amygdala enlargement, weaker functional connectivity between the amygdala and frontal emotional-regulation centers, altered glutamate/glutamine ratios, and lower visuospatial memory scores. Building on those findings with a much larger sample of 82 long-term AAS gymcels and 68 non-using gymcels, they found widespread cortical thinning most notably in prefrontal regions governing executive function and impulse control alongside reduced total gray matter volume that correlated with longer cumulative durations of use. Because both investigations were cross-sectional observational snapshots rather than controlled trials, they demonstrate strong associations between prolonged high-dose exposure and structural brain differences.
Taken together, these neuroimaging findings suggest that prolonged, high-dose AAS exposure disrupts neural integrity through overlapping mechanisms of excitotoxicity, oxidative stress, and suppressed neurotrophic signaling leading to measurable reductions in cortical thickness, gray matter volume, and fronto-limbic connectivity. Cerebrolysin could counteract these downstream effects by mimicking endogenous neurotrophic factors to reactivate cellular survival pathways, buffer glutamate-mediated excitotoxicity, and promote synaptic remodeling in affected prefrontal and hippocampal regions.
(No clinical research has been done on this tho.)
Comparison of Memantine and Cerebrolysin
| Memantine | Cerebrolysin |
|---|---|---|
Main mechanism | NMDA receptor antagonism | Proposed neurotrophic and neurorestorative activity |
Primary research focus | Glutamatergic signalling and excitotoxicity | Neuronal survival and plasticity |
Proposed neuroprotective pathway | Regulation of excessive NMDA activity | Neurotrophic and intracellular survival signalling (PI3K/Akt, CREB) |
The substances have different pharmacological profiles. Memantine acts primarily on NMDA receptor-associated ion channels, whereas Cerebrolysin has been investigated for a broader range of biological effects.
Complementarity
The proposed combination of memantine and Cerebrolysin is sometimes discussed in theoretical terms because they influence different aspects of neuronal function. Memantine primarily affects NMDA receptor activity and excitatory neurotransmission, while Cerebrolysin has been investigated for effects on neurotrophic signalling, neuronal survival, and neuroplasticity. Their mechanisms are quite different but appear complementary: Memantine regulates excessive excitatory signalling, whereas Cerebrolysin may influence the processes involved in maintaining and supporting neuronal function.
Conclusion
Both Memantine and Cerebrolysin have attracted interest for their potential to protect neuronal function, although they approach this through very different mechanisms. Memantine acts primarily as a non-competitive NMDA receptor antagonist, reducing excessive glutamatergic activity under certain pathological conditions. Cerebrolysin has been investigated for potential neurotrophic, neuroprotective, and neurorestorative effects involving neuronal survival and plasticity. Combining these two agents could produce a complementary "shield and repair" effect by targeting distinct stages of neuronal stress and recovery. By dampening excessive glutamatergic signaling and preventing pathological calcium influx at the NMDA receptor, Memantine would act upstream to stabilize vulnerable neurons against acute excitotoxicity and microglial overactivation. Simultaneously, Cerebrolysin would operate downstream by mimicking endogenous neurotrophic factors to reactivate intracellular survival cascades, stimulate dendritic spine regrowth, and support synaptic plasticity.
Thank you for reading, I spent a lot of time on this.
Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data - https://pubmed.ncbi.nlm.nih.gov/10465680/
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence - https://pubmed.ncbi.nlm.nih.gov/12973747/
Memantine in Moderate-to-Severe Alzheimer’s Disease - https://pubmed.ncbi.nlm.nih.gov/12672860/
Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil - https://pubmed.ncbi.nlm.nih.gov/14734594/
Memantine Treatment in Patients with Mild to Moderate Alzheimer’s Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study - https://pubmed.ncbi.nlm.nih.gov/18334761/
Memantine as a neuroprotective agent in ischemic stroke: Preclinical and clinical analysis - https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1096372/full
Memantine protects the cultured rat hippocampal neurons treated by NMDA and amyloid β1–42 - https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1269664/full
Revisiting Memantine: NMDA Modulation and Its Growing Relevance in Seizure Care - https://www.pharmacytimes.com/view/...ion-and-its-growing-relevance-in-seizure-care
The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance - https://pubmed.ncbi.nlm.nih.gov/14628195/
Effects of Cerebrolysin™ on neurogenesis in an APP transgenic model of Alzheimer’s disease - https://pubmed.ncbi.nlm.nih.gov/17131129/
Cerebrolysin in Patients With Acute Ischemic Stroke in Asia - https://pubmed.ncbi.nlm.nih.gov/22282884/
Cerebrolysin and Recovery After Stroke (CARS) - https://pubmed.ncbi.nlm.nih.gov/26564102/
Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I—a randomized, placebo-controlled, double-blind, Asian-Pacific trial - https://pubmed.ncbi.nlm.nih.gov/31494820/
Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial - https://pubmed.ncbi.nlm.nih.gov/31897941/
Cerebrolysin for acute ischaemic stroke - https://pubmed.ncbi.nlm.nih.gov/37818733/
Cerebrolysin Mode of Action Overview - https://www.cerebrolysin.com/cerebrolysin/mode-of-action
The Pharmacology of Neurotrophic Treatment with Cerebrolysin: Brain Protection and Repair to Counteract Pathologies of Acute and Chronic Neurological Disorders - https://pubmed.ncbi.nlm.nih.gov/22514792/
Cerebrolysin Alleviating Effect on Glutamate-Mediated Neuroinflammation Via Glutamate Transporters and Oxidative Stress - https://pubmed.ncbi.nlm.nih.gov/36333611/
Nanomolar concentrations of anabolic-androgenic steroids amplify excitotoxic neuronal death in mixed mouse cortical cultures - https://pubmed.ncbi.nlm.nih.gov/17662252/
Brain and cognition abnormalities in long-term anabolic-androgenic steroid users - https://pubmed.ncbi.nlm.nih.gov/25986964/
Structural Brain Imaging of Long-Term Anabolic-Androgenic Steroid Users and Nonusing Weightlifters - https://doi.org/10.1016/j.biopsych.2016.06.017
Long-term Anabolic–Androgenic Steroid Use Is Associated With Deviant Brain Aging - https://pubmed.ncbi.nlm.nih.gov/33811018/
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence - https://pubmed.ncbi.nlm.nih.gov/12973747/
Memantine in Moderate-to-Severe Alzheimer’s Disease - https://pubmed.ncbi.nlm.nih.gov/12672860/
Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil - https://pubmed.ncbi.nlm.nih.gov/14734594/
Memantine Treatment in Patients with Mild to Moderate Alzheimer’s Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study - https://pubmed.ncbi.nlm.nih.gov/18334761/
Memantine as a neuroprotective agent in ischemic stroke: Preclinical and clinical analysis - https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1096372/full
Memantine protects the cultured rat hippocampal neurons treated by NMDA and amyloid β1–42 - https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1269664/full
Revisiting Memantine: NMDA Modulation and Its Growing Relevance in Seizure Care - https://www.pharmacytimes.com/view/...ion-and-its-growing-relevance-in-seizure-care
The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance - https://pubmed.ncbi.nlm.nih.gov/14628195/
Effects of Cerebrolysin™ on neurogenesis in an APP transgenic model of Alzheimer’s disease - https://pubmed.ncbi.nlm.nih.gov/17131129/
Cerebrolysin in Patients With Acute Ischemic Stroke in Asia - https://pubmed.ncbi.nlm.nih.gov/22282884/
Cerebrolysin and Recovery After Stroke (CARS) - https://pubmed.ncbi.nlm.nih.gov/26564102/
Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I—a randomized, placebo-controlled, double-blind, Asian-Pacific trial - https://pubmed.ncbi.nlm.nih.gov/31494820/
Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial - https://pubmed.ncbi.nlm.nih.gov/31897941/
Cerebrolysin for acute ischaemic stroke - https://pubmed.ncbi.nlm.nih.gov/37818733/
Cerebrolysin Mode of Action Overview - https://www.cerebrolysin.com/cerebrolysin/mode-of-action
The Pharmacology of Neurotrophic Treatment with Cerebrolysin: Brain Protection and Repair to Counteract Pathologies of Acute and Chronic Neurological Disorders - https://pubmed.ncbi.nlm.nih.gov/22514792/
Cerebrolysin Alleviating Effect on Glutamate-Mediated Neuroinflammation Via Glutamate Transporters and Oxidative Stress - https://pubmed.ncbi.nlm.nih.gov/36333611/
Nanomolar concentrations of anabolic-androgenic steroids amplify excitotoxic neuronal death in mixed mouse cortical cultures - https://pubmed.ncbi.nlm.nih.gov/17662252/
Brain and cognition abnormalities in long-term anabolic-androgenic steroid users - https://pubmed.ncbi.nlm.nih.gov/25986964/
Structural Brain Imaging of Long-Term Anabolic-Androgenic Steroid Users and Nonusing Weightlifters - https://doi.org/10.1016/j.biopsych.2016.06.017
Long-term Anabolic–Androgenic Steroid Use Is Associated With Deviant Brain Aging - https://pubmed.ncbi.nlm.nih.gov/33811018/
@the wizard @Mr. Oxytocin @susborgerwaffen
@Skanta @Raynal @Dave. @Hyporoxin @hatred&gasoline @Dysregulated @dookiebootybutt59 @GoldenRatio @CoolManletGuy @ineedbones @Ropemaxer @MusicEnthusiast @empathic man @Bitdancer @cedrigo @laydownrot fan @AssMan @Aylan @aylan-but-fag @acehvh @number1fakecel @cold @sleepy. @Chakiyo @iloveadmins
Rest in peace @Dimorphic

, mirin effort and actually seems a worthy read

